Histogen Valuation
| HSTODelisted Stock | USD 0.03 0.00 0.00% |
Histogen seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of Histogen from evaluating the firm fundamentals such as Return On Asset of -0.54, shares outstanding of 4.27 M, and Return On Equity of -1.2 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Histogen's price fluctuation is out of control at this time. Calculation of the real value of Histogen is based on 3 months time horizon. Increasing Histogen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Histogen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Histogen Stock. However, Histogen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.027 | Real 0.0257 | Hype 0.03 |
The intrinsic value of Histogen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Histogen's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Histogen helps investors to forecast how Histogen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Histogen more accurately as focusing exclusively on Histogen's fundamentals will not take into account other important factors: Histogen Total Value Analysis
Histogen is currently anticipated to have valuation of (4.46 M) with market capitalization of 85.44 K, debt of 4.63 M, and cash on hands of 12.6 M. The negative valuation of Histogen may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Histogen fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(4.46 M) | 85.44 K | 4.63 M | 12.6 M |
Histogen Investor Information
The company has price-to-book (P/B) ratio of 0.02. Some equities with similar Price to Book (P/B) outperform the market in the long run. Histogen recorded a loss per share of 2.81. The entity last dividend was issued on the 27th of May 2020. The firm had 1:20 split on the 3rd of June 2022. Based on the analysis of Histogen's profitability, liquidity, and operating efficiency, Histogen is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Histogen Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Histogen has an asset utilization ratio of 0.0996 percent. This suggests that the Company is making $9.96E-4 for each dollar of assets. An increasing asset utilization means that Histogen is more efficient with each dollar of assets it utilizes for everyday operations.Histogen Ownership Allocation
Roughly 97.15 (percent) of Histogen outstanding shares are held by general public with 2.85 % owned by insiders and only 0.0 pct. by outside corporations.Histogen Profitability Analysis
The company reported the previous year's revenue of 19 K. Net Loss for the year was (12.38 M) with loss before overhead, payroll, taxes, and interest of (3.26 M).About Histogen Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Histogen. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Histogen based exclusively on its fundamental and basic technical indicators. By analyzing Histogen's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Histogen's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Histogen. We calculate exposure to Histogen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Histogen's related companies.Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California. Histogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Histogen Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 3.2 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Histogen Stock
If you are still planning to invest in Histogen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Histogen's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |